AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
Hosted on MSN1d
AstraZeneca Expands U.S. Investment Plan“If requested we will fully cooperate with the authorities.” AstraZeneca last week said its China head, Leon Wang, was ...
AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...
The jobs include roles in engineering and technical services and global supply chain functions. Read more at straitstimes.com ...
AstraZeneca said its China president Leon Wang is under investigation and the drugmaker would cooperate with Chinese ...
Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...
AstraZeneca today announces $3.5 billion of capital investment ... or concerns about the products and services offered on ...
JPMorgan Chase & Co. reissued their overweight rating on shares of AstraZeneca (LON:AZN – Free Report) in a report issued on ...
AstraZeneca has put a £450m investment in Britain under review ... The Government is seeking to reduce the amount of state ...
The pharma giant confirmed that Wang Lei, the executive vice president who oversaw AstraZeneca’s rapid expansion in China, is ...
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the ...
The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback